IN2014DN06952A - - Google Patents
Info
- Publication number
- IN2014DN06952A IN2014DN06952A IN6952DEN2014A IN2014DN06952A IN 2014DN06952 A IN2014DN06952 A IN 2014DN06952A IN 6952DEN2014 A IN6952DEN2014 A IN 6952DEN2014A IN 2014DN06952 A IN2014DN06952 A IN 2014DN06952A
- Authority
- IN
- India
- Prior art keywords
- dressings
- amino acid
- xaa
- peptide
- seq
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- VWJLJHZPMZGDDV-HOCDWTQPSA-N (4s)-4-amino-5-[[(2s)-1-[[(2s,3s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CCC(O)=O)C1=CN=CN1 VWJLJHZPMZGDDV-HOCDWTQPSA-N 0.000 abstract 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 108010049003 Fibrinogen Proteins 0.000 abstract 1
- 102000008946 Fibrinogen Human genes 0.000 abstract 1
- TVDHVLGFJSHPAX-UWVGGRQHSA-N Gly-His-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 TVDHVLGFJSHPAX-UWVGGRQHSA-N 0.000 abstract 1
- JYPCXBJRLBHWME-IUCAKERBSA-N Gly-Pro-Arg Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JYPCXBJRLBHWME-IUCAKERBSA-N 0.000 abstract 1
- 108090000190 Thrombin Proteins 0.000 abstract 1
- 229940030225 antihemorrhagics Drugs 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 229940012952 fibrinogen Drugs 0.000 abstract 1
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 abstract 1
- 108010023364 glycyl-histidyl-arginine Proteins 0.000 abstract 1
- 108010025801 glycyl-prolyl-arginine Proteins 0.000 abstract 1
- 230000000025 haemostatic effect Effects 0.000 abstract 1
- 230000023597 hemostasis Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 229960004072 thrombin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0036—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/0047—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L24/0073—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/108—Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Composite Materials (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Haemostatic wound dressings are described. The dressings comprise a non colloidal porous dressing material and a plurality of fibrinogen binding peptides immobilised to the non colloidal porous dressing material wherein each fibrinogen binding peptide comprises: an amino acid sequence Gly Pro Arg Xaa (SEQ ID NO: 1 ) at an amino terminal end of the peptide wherein Xaa is any amino acid other than Val preferably Pro Sar or Leu; or an amino acid sequence Gly His Arg Xaa (SEQ ID NO: 2) at an amino terminal end of the peptide wherein Xaa is any amino acid other than Pro. The dressings are able to accelerate haemostasis without requiring enzymatic activity. In particular the dressings to do not rely on the action of exogenous thrombin and can be stored long term at room temperature in solution. Methods of making the dressings and use of the dressings to control bleeding are also described.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1201751.3A GB201201751D0 (en) | 2012-02-01 | 2012-02-01 | Haemostatic wound dressing |
| PCT/GB2013/050237 WO2013114132A1 (en) | 2012-02-01 | 2013-02-01 | Haemostatic wound dressing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN06952A true IN2014DN06952A (en) | 2015-04-10 |
Family
ID=45876478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN6952DEN2014 IN2014DN06952A (en) | 2012-02-01 | 2013-02-01 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9808553B2 (en) |
| EP (1) | EP2809365B8 (en) |
| JP (1) | JP6258868B2 (en) |
| KR (1) | KR102168157B1 (en) |
| CN (1) | CN104114198B (en) |
| ES (1) | ES2879558T3 (en) |
| GB (2) | GB201201751D0 (en) |
| HR (1) | HRP20211112T8 (en) |
| IN (1) | IN2014DN06952A (en) |
| RU (1) | RU2661036C2 (en) |
| WO (1) | WO2013114132A1 (en) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0516091D0 (en) * | 2005-08-04 | 2005-09-14 | Haemostatix Ltd | Therapeutic agent |
| GB0808376D0 (en) | 2008-05-08 | 2008-06-18 | Bristol Myers Squibb Co | Wound dressing |
| GB0817796D0 (en) | 2008-09-29 | 2008-11-05 | Convatec Inc | wound dressing |
| GB201020236D0 (en) | 2010-11-30 | 2011-01-12 | Convatec Technologies Inc | A composition for detecting biofilms on viable tissues |
| WO2012078784A1 (en) | 2010-12-08 | 2012-06-14 | Convatec Technologies Inc. | Wound exudate system accessory |
| JP5965409B2 (en) | 2010-12-08 | 2016-08-03 | コンバテック・テクノロジーズ・インコーポレイテッドＣｏｎｖａｔｅｃ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ | Integrated system for assessing wound exudate |
| GB201115182D0 (en) | 2011-09-02 | 2011-10-19 | Trio Healthcare Ltd | Skin contact material |
| GB2497406A (en) | 2011-11-29 | 2013-06-12 | Webtec Converting Llc | Dressing with a perforated binder layer |
| GB201120693D0 (en) | 2011-12-01 | 2012-01-11 | Convatec Technologies Inc | Wound dressing for use in vacuum therapy |
| CN105008611A (en) | 2012-12-20 | 2015-10-28 | 康沃特克科技公司 | Processing of chemically modified cellulosic fibres |
| GB201400292D0 (en) * | 2014-01-08 | 2014-02-26 | Haemostatix Ltd | Peptide dendrimers and agents |
| US12083245B2 (en) * | 2014-10-02 | 2024-09-10 | Wake Forest University Health Sciences | Amniotic membrane powder and its use in wound healing and tissue engineering constructs |
| GB201508020D0 (en) * | 2015-05-11 | 2015-06-24 | Haemostatix Ltd | Haemostatic material |
| GB201508014D0 (en) * | 2015-05-11 | 2015-06-24 | Haemostatix Ltd | Haemostatic device |
| GB201508024D0 (en) * | 2015-05-11 | 2015-06-24 | Haemostatix Ltd | Haemostatic compositions |
| US20170152556A1 (en) * | 2015-06-08 | 2017-06-01 | The Procter & Gamble Company | Methods for identifying circadian rhythm-dependent cosmetic agents for skin care compositions |
| AU2016313773B2 (en) * | 2015-09-01 | 2020-11-26 | Baxter International Inc. | Hemostatic material |
| GB2543307B (en) * | 2015-10-14 | 2020-12-09 | Selentus Science Ltd | Haemostatic device |
| CA3019445A1 (en) | 2016-03-30 | 2017-12-14 | Synovo Gmbh | Detecting microbial infection in wounds |
| TW201800069A (en) | 2016-03-30 | 2018-01-01 | 康華特科技有限公司 | Detecting microbial infection in wounds |
| WO2018009879A1 (en) | 2016-07-08 | 2018-01-11 | Convatec Technologies Inc. | Fluid flow sensing |
| CA3030151A1 (en) | 2016-07-08 | 2018-01-11 | Convatec Technologies Inc. | Fluid collection apparatus |
| MX2019000239A (en) | 2016-07-08 | 2019-09-06 | Convatec Technologies Inc | Flexible negative pressure system. |
| CN106344960B (en) * | 2016-09-20 | 2019-02-22 | 安徽思维特生物科技有限公司 | The hemostasis gel prepared using microcrystalline cellulose graft modification abortive calfskin collagenous fibres |
| IL256405A (en) * | 2017-12-19 | 2018-01-31 | Omrix Biopharmaceuticals Ltd | Wound dressing and a method for producing the same |
| GB2571080A (en) * | 2018-02-14 | 2019-08-21 | Medtrade Products Ltd | Haemostatic material |
| US12076215B2 (en) | 2019-06-03 | 2024-09-03 | Convatec Limited | Methods and devices to disrupt and contain pathogens |
| CN110448719B (en) * | 2019-06-28 | 2020-05-22 | 浙江大学 | Silk fibroin-polypeptide electrospun membrane for promoting blood coagulation and preparation method thereof |
| US11331221B2 (en) | 2019-12-27 | 2022-05-17 | Convatec Limited | Negative pressure wound dressing |
| US11771819B2 (en) | 2019-12-27 | 2023-10-03 | Convatec Limited | Low profile filter devices suitable for use in negative pressure wound therapy systems |
| GB2596525A (en) * | 2020-06-26 | 2022-01-05 | Fujifilm Corp | Modified gelatins |
| CN112206307B (en) * | 2020-09-15 | 2023-12-05 | 广州领晟医疗科技有限公司 | Injectable temperature-sensitive hydrogel and preparation method and application thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3175003D1 (en) | 1981-06-25 | 1986-08-28 | Serapharm Gmbh & Co Kg | Enriched plasma derivative for promoting wound sealing and wound healing |
| GB9107628D0 (en) | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
| EP1338648B1 (en) | 1992-05-29 | 2005-11-30 | The University Of North Carolina At Chapel Hill | Pharmaceutically acceptable fixed-dried human blood platelets |
| AU702955B2 (en) | 1996-05-17 | 1999-03-11 | Quadrant Healthcare (Uk) Limited | Microparticles and their use in wound therapy |
| ES2232862T3 (en) | 1996-10-21 | 2005-06-01 | Quadrant Drug Delivery Limited | SUBSTITUTES OF PLATES AND CONJUGATION PROCEDURES APPROPRIATE FOR PREPARATION. |
| US6891077B2 (en) | 2001-07-25 | 2005-05-10 | The United States Of America As Represented By The Secretary Of The Army | Fibrinogen bandages and arterial bleeding models and methods of making and using thereof |
| WO2003088990A1 (en) * | 2002-04-15 | 2003-10-30 | American National Red Cross | Plasma protein-binding ligands |
| US20040101546A1 (en) * | 2002-11-26 | 2004-05-27 | Gorman Anne Jessica | Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents |
| GB2410687A (en) | 2002-11-20 | 2005-08-10 | Univ Bar Ilan | Biological glue based on thrombin-conjugated nanoparticles |
| DE10323794A1 (en) | 2003-05-23 | 2004-12-09 | Dr. Suwelack Skin & Health Care Ag | Process for the production of alginate-containing porous moldings |
| CA2530032C (en) | 2003-06-16 | 2015-11-24 | Loma Linda University Medical Center | Deployable multifunctional hemostatic agent |
| US7927626B2 (en) | 2003-08-07 | 2011-04-19 | Ethicon, Inc. | Process of making flowable hemostatic compositions and devices containing such compositions |
| US7186684B2 (en) | 2003-08-07 | 2007-03-06 | Ethicon, Inc. | Hemostatic device containing a protein precipitate |
| GB0323378D0 (en) * | 2003-10-07 | 2003-11-05 | Univ Leicester | Therapeutic agent |
| MX2007000918A (en) | 2004-07-22 | 2007-12-04 | Hemo Nanoscience Llc | Compositions and methods for treating excessive bleeding. |
| US9358318B2 (en) | 2004-10-20 | 2016-06-07 | Ethicon, Inc. | Method of making a reinforced absorbable multilayered hemostatic wound dressing |
| GB0516091D0 (en) * | 2005-08-04 | 2005-09-14 | Haemostatix Ltd | Therapeutic agent |
| GB0623607D0 (en) * | 2006-11-27 | 2007-01-03 | Haemostatix Ltd | Tissue adhesive |
| KR101428122B1 (en) * | 2006-12-15 | 2014-08-07 | 라이프본드 엘티디. | Gelatin-transglutaminase hemostatic dressings and sealants |
| WO2009018126A2 (en) * | 2007-08-01 | 2009-02-05 | Ethicon, Inc. | Collagen-related peptides and uses thereof |
| US8512740B2 (en) | 2008-03-26 | 2013-08-20 | Baxter International Inc. | Fibrin foam and process for making |
| US20100021527A1 (en) | 2008-07-25 | 2010-01-28 | Chunlin Yang | Collagen-related peptides and uses thereof and hemostatic foam substrates |
| US8513380B2 (en) | 2009-07-09 | 2013-08-20 | Georgia Tech Research Corporation | Peptides for binding fibrinogen and fibrin |
-
2012
- 2012-02-01 GB GBGB1201751.3A patent/GB201201751D0/en not_active Ceased
-
2013
- 2013-02-01 IN IN6952DEN2014 patent/IN2014DN06952A/en unknown
- 2013-02-01 KR KR1020147023963A patent/KR102168157B1/en active IP Right Grant
- 2013-02-01 RU RU2014132763A patent/RU2661036C2/en active
- 2013-02-01 EP EP13708510.6A patent/EP2809365B8/en active Active
- 2013-02-01 US US14/376,023 patent/US9808553B2/en active Active
- 2013-02-01 ES ES13708510T patent/ES2879558T3/en active Active
- 2013-02-01 CN CN201380007527.0A patent/CN104114198B/en active Active
- 2013-02-01 JP JP2014555315A patent/JP6258868B2/en active Active
- 2013-02-01 WO PCT/GB2013/050237 patent/WO2013114132A1/en active Application Filing
- 2013-02-01 GB GB1301847.8A patent/GB2501348B/en active Active
-
2021
- 2021-07-12 HR HRP20211112TT patent/HRP20211112T8/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20211112T1 (en) | 2021-10-15 |
| WO2013114132A1 (en) | 2013-08-08 |
| US20150071985A1 (en) | 2015-03-12 |
| EP2809365A1 (en) | 2014-12-10 |
| JP2015506764A (en) | 2015-03-05 |
| US9808553B2 (en) | 2017-11-07 |
| RU2661036C2 (en) | 2018-07-11 |
| CN104114198A (en) | 2014-10-22 |
| GB201201751D0 (en) | 2012-03-14 |
| ES2879558T3 (en) | 2021-11-22 |
| JP6258868B2 (en) | 2018-01-10 |
| RU2014132763A (en) | 2016-03-27 |
| GB2501348B (en) | 2020-06-24 |
| HRP20211112T8 (en) | 2022-01-21 |
| CN104114198B (en) | 2018-09-04 |
| EP2809365B8 (en) | 2021-06-23 |
| KR102168157B1 (en) | 2020-10-21 |
| EP2809365B1 (en) | 2021-05-12 |
| GB2501348A (en) | 2013-10-23 |
| KR20140121864A (en) | 2014-10-16 |
| GB201301847D0 (en) | 2013-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN06952A (en) | ||
| NZ609959A (en) | Modified factor ix polypeptides and uses thereof | |
| RS53505B1 (en) | Oxyntomodulin peptide analogue | |
| HRP20180135T1 (en) | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof | |
| WO2010107185A2 (en) | Composition for skin regeneration, containing a secretion in the culture of an embryonic stem cell-derived endothelial progenitor cell or fractions thereof, and use thereof | |
| PE20181206A1 (en) | SPECIFIC LIVER CONSTRUCTIONS, FACTOR VIII EXPRESSION CASSETTES AND METHODS OF USE OF THESE | |
| WO2012082950A3 (en) | Chimeric fibronectin matrix mimetics and uses thereof | |
| MX2014011600A (en) | Nutritive fragments, proteins and methods. | |
| NZ602845A (en) | Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof | |
| MX339277B (en) | Immunity inducer. | |
| WO2023284900A3 (en) | Recombinant human collagen polypeptide and use thereof | |
| PH12015500461A1 (en) | Novel il-17a binding molecules and medical uses thereof | |
| NZ630469A (en) | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases | |
| MX2015011243A (en) | Peptides for use in the topical treatment of retinal neurodegenerative disesases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role. | |
| PH12016500101A1 (en) | Protease-resistant peptide ligands | |
| UA103216C2 (en) | Polypeptide with xylanase activity | |
| WO2009081368A3 (en) | Cosmetic use desmoglein i-type proteins | |
| NZ610389A (en) | Use of a composition comprising an antimicrobial peptide as a food preservative | |
| CN110453292B (en) | Method for efficiently screening fibrinogen by using phage antibody library | |
| BR112015013387B8 (en) | MODIFIED COILED-COIL-TYPE PROTEINS HAVING IMPROVED PROPERTIES | |
| JP2020513810A5 (en) | ||
| MX354156B (en) | Dipeptide comprising a non-proteogenic amino acid. | |
| NZ586074A (en) | LCLRP peptides, constructs and uses thereof | |
| RS54422B1 (en) | Inhibitors of apoptosis and uses thereof | |
| WO2018080148A3 (en) | Three-dimensional cell culture system comprising peg-based hydrogel |